Multidrug resistance

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug

Tuberculosis is currently the infectious disease that causes the most deaths worldwide. Of particular concern is the increasing emergence of multidrug-resistant tuberculosis bacteria, particularly in

Bacteria that are resistant to broad-spectrum antibiotics from the carbapenem group are increasingly posing major problems for healthcare systems worldwide. They can cause serious infections and

From 18 to 24 November, the “World AMR Awareness Week” (WAAW), a global campaign proclaimed by WHO, aims to draw attention to the near-pandemic rise in infections caused by resistant microbial

With one of the highest tuberculosis (TB) incidences (368 cases/100,000 population) in the African region, Mozambique is particularly affected by the TB epidemic. Drug-resistant TB is also a major

Today, UNITE4TB, an international public-private partnership striving to fast-track the development of innovative tuberculosis (TB) treatments, announced the start of its phase-IIb/c-clinical trial

Researchers from the German Center for Infection Research (DZIF) at the University of Cologne have conducted a study on the carbapenem-resistant bacterium Acinetobacter baumannii. The pathogen was

Antibiotic-resistant bacteria pose a major challenge to healthcare systems worldwide. Due to numerous resistance mechanisms, infections with the pathogen Pseudomonas aeruginosa are particularly feared

DZIF scientist Dr Janko Sattler, a medical specialist at the Institute for Medical Microbiology, Immunology and Hygiene at the University Hospital Cologne, was awarded the bioMérieux Diagnostics Prize

More and more bacterial pathogens are developing resistance. There is an increasing risk that current drugs will no longer be effective against infectious diseases. Scientists around the world are